1. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

receptor tyrosine kinase

" in MedChemExpress (MCE) Product Catalog:

166

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

7

Peptides

5

Inhibitory Antibodies

7

Natural
Products

145

Recombinant Proteins

9

Isotope-Labeled Compounds

24

Antibodies

3

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112412

    PDGF receptor tyrosine kinase Inhibitor III

    PDGFR Neurological Disease
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .
    PDGFR Tyrosine Kinase Inhibitor III
  • HY-18963

    RG-14355

    EGFR Cancer
    Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
    Lavendustin A
  • HY-18314
    GW 441756
    5+ Cited Publications

    Trk Receptor Apoptosis Neurological Disease Cancer
    GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC50=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth .
    GW 441756
  • HY-18316

    JAK Inflammation/Immunology
    RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .
    RO495
  • HY-101756

    SDZ-LAP 977

    EGFR Cancer
    SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.
    SDZ281-977
  • HY-101962

    Insulin Receptor Metabolic Disease
    HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
    HNMPA
  • HY-114667

    EGFR Others
    Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC50 value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .
    Lavendustin C6
  • HY-164394

    c-Met/HGFR Cancer
    EMD 1204831 is a potent and highly selective c-Met inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC50 of 9 nM. EMD 1204831 can be utilized in cancer research .
    EMD 1204831
  • HY-116116

    SIM010603

    c-Kit RET VEGFR Cancer
    Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
    Tafetinib
  • HY-124146

    Syk Inflammation/Immunology
    BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .
    BI1002494
  • HY-18007
    ALW-II-41-27
    20+ Cited Publications

    Eph receptor tyrosine kinase inhibitor

    Ephrin Receptor Cancer
    ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC50 of 11 nM for Eph2.
    ALW-II-41-27
  • HY-18840
    BBT594
    3 Publications Verification

    NVP-BBT594

    RET Cancer
    BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
    BBT594
  • HY-159503

    3D185 free base; HH185 free base

    Others Cancer
    Segigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect .
    Segigratinib
  • HY-152845

    Anaplastic lymphoma kinase (ALK) Cancer
    Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor. Ficonalkib, can be used as an antineoplastic agent .
    Ficonalkib
  • HY-101429

    Tyrphostin RG13022

    EGFR Cancer
    RG13022 is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC50 of 4 μM.
    RG13022
  • HY-12963
    Dubermatinib
    5+ Cited Publications

    TP-0903

    TAM Receptor Apoptosis Cancer
    Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.
    Dubermatinib
  • HY-13892

    CHIR-258 dilactic acid; TKI258 dilactic acid

    VEGFR Cancer
    Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .
    Dovitinib dilactic acid
  • HY-100673

    Trk Receptor Neurological Disease
    LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
    LM22A-4
  • HY-10331S

    BAY 73-4506-d3

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].
    Regorafenib-d3
  • HY-148742

    RET Cancer
    RET-IN-21 is an inhibitor of receptor tyrosine kinase (RET), with the IC 50 of 4.4 μM, that has antitumor activity .
    RET-IN-21
  • HY-145626

    BA302

    ADC Antibody Cancer
    Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
    Ozuriftamab
  • HY-112096
    eCF506
    2 Publications Verification

    Src Cancer
    eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC50 of less than 0.5 nM.
    eCF506
  • HY-P0177

    Ephrin Receptor Metabolic Disease
    123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a Ki value of 0.65 μM .
    123C4
  • HY-10407
    SU 5402
    5+ Cited Publications

    VEGFR FGFR PDGFR Cancer
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
    SU 5402
  • HY-P99969

    EGFR Cancer
    Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
    Inetetamab
  • HY-P1776

    Insulin Receptor Metabolic Disease
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)
  • HY-101957
    AG 1295
    3 Publications Verification

    PDGFR Cardiovascular Disease
    AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .
    AG 1295
  • HY-12806

    EGFR Cancer
    AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC50 value of 8.194 .
    AG1557
  • HY-10501
    SU14813
    1 Publications Verification

    PDGFR VEGFR c-Kit Cancer
    SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
    SU14813
  • HY-10501A
    SU14813 maleate
    1 Publications Verification

    PDGFR VEGFR c-Kit Cancer
    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
    SU14813 maleate
  • HY-147316

    Others Cancer
    TP-5801 is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity .
    TP-5801
  • HY-120857

    PD 158294

    Others Others
    BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC50=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.
    BPIQ-II hydrochloride
  • HY-118144

    BCRP Src Cancer
    PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC50s of 6 nM and 8 nM for Src and Abl, respectively. PD166326 exhibits antileukemic activity .
    PD166326
  • HY-153012

    TAM Receptor c-Fms Cancer
    Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM .
    Axl/Mer/CSF1R-IN-1
  • HY-147316A

    Others Cancer
    TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity .
    TP-5801 TFA
  • HY-15772S3

    asandeutertinibum; Osimertinib-d3; AZD-9291-d3

    EGFR Cancer
    Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .
    Asandeutertinib
  • HY-144424

    Trk Receptor Cancer
    Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC50 = 1.4, 1.8 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .
    Trk-IN-11
  • HY-112452

    VEGFR FGFR PDGFR c-Kit Apoptosis Cancer
    SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .
    SU11652
  • HY-13979
    DDR1-IN-1
    3 Publications Verification

    Discoidin Domain Receptor Cancer
    DDR1-IN-1 is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM) .
    DDR1-IN-1
  • HY-13979A

    Discoidin Domain Receptor Cancer
    DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM) .
    DDR1-IN-1 dihydrochloride
  • HY-111969
    BT18
    1 Publications Verification

    GDNF Receptor Neurological Disease
    BT18 is a molecule mimic with function similar to glial cell line-derived neurotrophic factor (GDNF) . BT18 shows an effect on GDNF family receptor GFRα1 and RET receptor tyrosine kinase RetA function .
    BT18
  • HY-128571

    FLT3 Cancer
    FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia .
    FLT3-IN-4
  • HY-101959

    AG213

    EGFR Topoisomerase Cancer
    Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC50=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC50=2.4 μM) and topoisomerase II (IC100=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells .
    Tyrphostin AG213
  • HY-13896
    PD168393
    2 Publications Verification

    EGFR Autophagy Apoptosis Cancer
    PD168393?is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC50=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .
    PD168393
  • HY-101837

    Others Inflammation/Immunology
    CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .
    CGP 53716
  • HY-118203

    FGFR PDGFR Insulin Receptor Cancer
    SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer .
    SU4984
  • HY-110367A

    Src Others
    LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor. LCB 03-0110 suppresses scar formation by inhibiting fibroblast and macrophage activation .
    LCB 03-0110
  • HY-156635

    Tie VEGFR Cardiovascular Disease
    TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis .
    TIE-2/VEGFR-2 kinase-IN-3
  • HY-156637

    Tie VEGFR Cardiovascular Disease
    TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis .
    TIE-2/VEGFR-2 kinase-IN-4
  • HY-P99733

    ADC Antibody TAM Receptor Cancer
    Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
    Mipasetamab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: